These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 11918946)

  • 1. Is radiation nephropathy caused by yttrium-90?
    Otte A; Weiner SM; Cybulla M
    Lancet; 2002 Mar; 359(9310):979; author reply 979. PubMed ID: 11918946
    [No Abstract]   [Full Text] [Related]  

  • 2. Radiation nephropathy caused by yttrium 90.
    Cohen EP; Moulder JE; Robbins ME
    Lancet; 2001 Sep; 358(9287):1102-3. PubMed ID: 11594331
    [No Abstract]   [Full Text] [Related]  

  • 3. 90Y-DOTATOC and nephrotoxicity.
    Otte A; Cybulla M; Weiner SM
    Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1543. PubMed ID: 12537003
    [No Abstract]   [Full Text] [Related]  

  • 4. Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients?
    Konijnenberg MW
    Cancer Biother Radiopharm; 2003 Aug; 18(4):619-25. PubMed ID: 14503958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis.
    Behr TM; Béhé M; Kluge G; Gotthardt M; Schipper ML; Gratz S; Arnold R; Becker W; Goldenberg DM
    Eur J Nucl Med Mol Imaging; 2002 Feb; 29(2):277-9. PubMed ID: 11926391
    [No Abstract]   [Full Text] [Related]  

  • 6. Kidney failure after treatment with 90Y-DOTATOC.
    Schumacher T; Waldherr C; Mueller-Brand J; Maecke H
    Eur J Nucl Med Mol Imaging; 2002 Mar; 29(3):435. PubMed ID: 12002721
    [No Abstract]   [Full Text] [Related]  

  • 7. New advances in peptide receptor radionuclide therapy.
    de Jong M; Krenning E
    J Nucl Med; 2002 May; 43(5):617-20. PubMed ID: 11994523
    [No Abstract]   [Full Text] [Related]  

  • 8. Is (90)Y-DOTATOC treatment for neuroendocrine tumours safe?
    Cybulla M; Weiner SM; Otte A
    Med Sci Monit; 2002 Apr; 8(4):LE7. PubMed ID: 11951054
    [No Abstract]   [Full Text] [Related]  

  • 9. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
    Vallabhajosula S; Goldsmith SJ; Hamacher KA; Kostakoglu L; Konishi S; Milowski MI; Nanus DM; Bander NH
    J Nucl Med; 2005 May; 46(5):850-8. PubMed ID: 15872360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The difference between medicine and magic is that magicians know what they are doing.
    Hicks RJ
    Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):1-4. PubMed ID: 25319711
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute leukaemia following low dose peptide receptor radionuclide therapy for an intestinal carcinoid.
    Merola E; Capurso G; Campana D; Panzuto F; Monarca B; Tomassetti P; Delle Fave G
    Dig Liver Dis; 2010 Jun; 42(6):457-8. PubMed ID: 19783489
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of kidney uptake of radiolabeled somatostatin analogs: amino acids or gelofusine?
    Rolleman EJ; de Jong M; Valkema R; Kwekkeboom D; Kam B; Krenning EP
    J Nucl Med; 2006 Oct; 47(10):1730-1; author reply 1731. PubMed ID: 17015911
    [No Abstract]   [Full Text] [Related]  

  • 13. Radiation dosimetry for indium-111-pentetreotide.
    Stabin MG; Kooij PP; Bakker WH; Inoue T; Endo K; Coveney J; de Jong R; Minegishi A
    J Nucl Med; 1997 Dec; 38(12):1919-22. PubMed ID: 9430470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
    Konijnenberg MW; Bijster M; Krenning EP; De Jong M
    J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts.
    DeNardo SJ; Kukis DL; Miers LA; Winthrop MD; Kroger LA; Salako Q; Shen S; Lamborn KR; Gumerlock PH; Meares CF; DeNardo GL
    J Nucl Med; 1998 May; 39(5):842-9. PubMed ID: 9591587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.
    Barone R; Borson-Chazot F; Valkema R; Walrand S; Chauvin F; Gogou L; Kvols LK; Krenning EP; Jamar F; Pauwels S
    J Nucl Med; 2005 Jan; 46 Suppl 1():99S-106S. PubMed ID: 15653658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetry in radionuclide therapies with 90Y-conjugates: the IEO experience.
    Cremonesi M; Ferrari M; Chinol M; Bartolomei M; Stabin MG; Sacco E; Fiorenza M; Tosi G; Paganelli G
    Q J Nucl Med; 2000 Dec; 44(4):325-32. PubMed ID: 11302260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodistribution of two octreotate analogs radiolabeled with indium and yttrium in rats.
    Laznickova A; Laznicek M; Trejtnar F; Maecke HR; Eisenwiener KP; Reubi JC
    Anticancer Res; 2010 Jun; 30(6):2177-84. PubMed ID: 20651367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. gamma-Interferon administration after 90yttrium radiolabeled antibody therapy: survival and hematopoietic toxicity studies.
    Thomas GE; Esteban JM; Raubitschek A; Wong JY
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):529-34. PubMed ID: 7852116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
    Frilling A; Weber F; Saner F; Bockisch A; Hofmann M; Mueller-Brand J; Broelsch CE
    Surgery; 2006 Dec; 140(6):968-76; discussion 976-7. PubMed ID: 17188146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.